Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
larnefpendekin alfa
- Development stage
- Unknown
- Lead developer
- Biocad
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravesical, Subcutaneous
01
Overview
BCD-225 (larnefpendekin alfa) is an interleukin-15 (IL-15) receptor superagonist developed by Biocad. It is a heterodimeric fusion protein consisting of human IL-15 fused to an IgG1 Fc domain and the extracellular sushi domain of the IL-15 receptor subunit alpha (IL-15Rα). By mimicking the trans-presentation of IL-15 by IL-15Rα, BCD-225 acts as a potent agonist of the IL-15 receptor complex, stimulating the activation and proliferation of CD8+ T cells and natural killer (NK) cells to enhance anti-tumor immunity. BCD-225 is being evaluated in clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC) in combination with the Bacillus Calmette-Guérin (BCG) vaccine, and has demonstrated preclinical efficacy in syngeneic models of colorectal cancer, melanoma, and bladder cancer both as a monotherapy and in combination with anti-PD-1 checkpoint inhibitors.
- Other names
- larnefpendekin alphalarnefpendekina alfalarnefpendekine alfa
02
Targets
IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)IL2RG (Interleukin-2 receptor gamma subunit)
Beyond the preview
Go deeper on larnefpendekin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on larnefpendekin alfa.